AKYA - Earnings call transcript Q1 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Akoya Biosciences First Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, today's call is being recorded. I would now like to turn the conference over to your host, Mr. Priyam Shah, Head of Investor Relations. Please go ahead, sir.

Priyam Shah

thank this everyone call. and us is operator, on today you, you who to joining Thank I'm at Akoya Shah, Biosciences. Priyam Head of Investor Relations

Officer; A financial the results today, McKelligon, the available first Financial On on have March for the Earlier and XX, press ended Executive is XXXX. Officer. released call Chief of Joe company's Akoya the today, website. quarter Driscoll, copy we Chief Brian release

that performance materially forward-looking to statements statements include call or XXXX. relate like factors. I'd remind that future during to or the Act to are statements meaning this make Federal the are from call Harbor statements implied Actual in a expectations Before Laws, to or we begin, of forward-looking may results Reform of those of forward-looking management you Securities in of statements. the Any the within which expressed will Litigation differ provisions this Private Securities of made Safe variety that predictions due results contained events, pursuant

list of any March future future you or Akoya as as the update guarantee factors aware the Akoya's statements, This call information events risks financial Risk you and revise disclaims conference of otherwise. the to our except and or of a and We performance. live information, May because XXXX. intention these Commission forward-looking section that the obligation, these law, should the with required of of refer please or only Exchange on are and broadcast XX-K projections estimates to whether Factors X, is any not accurate or new statements filed contains only time-sensitive by today, business, Securities and XXXX. Form to uncertainties with be consider considered XX, urge associated description and For should be

on investor the you H.C. hope Lastly upcoming we're be of that, with I in-person many to road. the see of Akoya May, call Wainwright America, UBS in we participating throughout to while will conferences turn Brian. Bank will and the And and over

Brian McKelligon

afternoon for to good XXXX, and of strong spatial most industry's today. Priyam, full you start or System, you, Akoya and biology thank the PhenoCycler-Fusion solution everyone, and new by the us launch evening commercial highlighted Thank powerful on the fastest our had a to very joining market.

quarter first million, quarter record was XX% over another The the revenue representing year. of growth prior $XX.X

units adoption instruments instruments we base an System XX new XX resulting PhenoCyclers sold five the quarter of as customers the of our installed and combine consisting you of Akoya QX, end XX of in the confidence Fusion further we demonstrates combined the XX by existing platforms. in strong new sold March When of During believe Fusion Fusion XX have of We initial shipped instruments the the and four of standalone PhenoImagers. at pre-released and XX, the installations. PhenoCycler-Fusion

drivers Our launch our organization and QX investments byproduct the efforts. our it expanded development execution of performance The represents commercial product the and key and our solid direct a signature is strong behind commitments to scale of quarter for made team Akoya were commercial Fusion, post-IPO as performance.

of market. the through momentum additional this expect and solutions the the theme to biology we gain remainder continue spatial new in as We launch year

Akoya, at focus biology. our spatial sole Here is

cell technologies tissue our the for method become slide industry We growth the The industry-leading are single over of and have speed whole the spatial rapid robustness and catalyzed enabling to optics phenotyping past years. of the cycling few analysis. our go-to

immunology, verticals meet such clinical customers needs and as across of translational research Our platforms discovery, more. neurobiology oncology, and the

publications success had more number than indicator base confirmation a will starting The We spatial that March over our last on large of have biology leading to date publications. instruments world continue. efforts drive a time of our tour nearly continuing installed In in and embarked we the this this the installed a rapidly which publications we in globally, to our is of this XXX trend platforms, high-impact have of key year. accelerating XXX is been at referenced doubles Five-hundred-and-thirty adoption publications year.

of XX team our across needs. is discuss cities biology Our globally seminars for holding and hands-on PhenoCycler-Fusion the demonstrations spatial customers' to to

our sales in the have and enabled high coupled efforts feedback We a XXXX. robust our to to been tour with to pleased has growing received of overwhelming on opportunities other us the positive and build this commercial marketing support objectives impact pipeline and

researchers' throughput, in translational by of the customer the PhenoCycler-Fusion the discovery speed, to development aim workflow the and was improve Our of plex desire. and providing combination

a the to by studies system perform as on then studies. validation can discovery use PhenoCycler-Fusion throughput and the our modular perform Fusion customers system, standalone high a Additionally platform as delivering high plex the

reduce XXX interactions and demonstrates month, data spatial cellular phenotyping This of our PhenoCycler-Fusion. can immune to the with the share excited that capability insights We as providing in we commercialize Enabling full has two breadth in capture, making can plex enables unprecedented both at do Throughout high accelerated and support scale to our higher sizes also these menu expanded last much unique into tissue high from of plex workflow to to the plex spatial content across analysis, a are Orleans will meeting markers proprietary move essentially compression both tumor New platform. we data expand throughput storage file biology. one platform for to XXXX, file HiPlex and biology algorithm To Akoya PhenoCycler-Fusion task. never multiplexing giving before At were our antibody researchers solutions using set capability possible. antibody the sharing this samples customers whole modules. AACR over modules the continue we workflow, a gigabytes, that simpler terabytes a deep

then throughput week a This the samples core speed to Fusion per CODEX samples combination discovery increasing PhenoImager design, and our workflow for more enables workflow on to to will us universal of Opal PhenoImager also Akoya new Our our single standalone of accelerate to release of the discovery over discovered already the journey biomarker of platform. commitment was plan protein PhenoCycler-Fusion bring XX our the drive into to to multi-omic AACR new chemistry The reagent that and panel at and samples further will ongoing, and higher to combines biomarker will at scale this larger will Commercial a the chemistry universal year. discovery and and true simplifying the to studies the automation method research. is end rollout throughput will utilization PhenoCycler-Fusion. per on will assay HT. commence validated on throughput platform and sensitivity clinical with previewed advance XX drive Also technology allow on XXX simplify be will our customers, validation of assay Fusion providing value from we that assay. components a high week. our remains the The validation. committed Biomarkers The chemistry revenue. biomarker universal improvements own from

delivering be will a PhenoCycler-Fusion. whole on We slide of suite spatial solutions transcriptomics the

launch product of RNA their Bio-Techne, on comes to with first partnership analysis designed System. automate which out our RNA is Our for chemistry our PhenoCycler-Fusion scope

As over spatial of adopted the most thousands widely many publications with X,XXX industry's RNA you of customers. scope and RNA solution for is know,

later and are and working spatial broad platform for applications, which proprietary be offer to plex for to on plex used expect studies our we RNA our applications anticipate transcriptomics range. enable in up We scale discovery primarily validation RNA upstream to year on lower it this targeted scope launch us own and technologies, the will Simultaneously X,XXX will capability.

month to We transcriptomic next are at clinical Orlando. in central launch solution we'll late the update the success. AGBT provide our Conference expect this an translational and partnerships proprietary to spatial and in XXXX In markets,

BioPharma is this or Advanced fundamental Group Solutions out of ABS Our Marlborough effort. to

key appointment phenotyping development, pathology and leadership will precision recently trial clinical spatial HT ABS. with trial our QX our We us first And journey, To partners platforms, supporting our critical expansion Medical central medicine spatial Akoya's drivers our IVD clinical XX was total continue into summarize development. of The cancer financial To our knowledge El-Gabry of reagents of to and of our PhenoImager our pleased extend Chief in over as the for success record markets. workflows robustness network ABS commercial the ongoing and clinical is that guide care. ABS research we advancing pipeline the higher-value with are diagnostic Ehab studies and through KOL run our revenue in and brings assay lab, business. we and the of years of instrument our as Dr. translational see vision to CLIA are Ehab enrollment clinical Akoya's translational performance. and workflow aim a help of Officer. announced certification and to strong applications, quarter rapid update, ABS our of clinical of in placements, drive on quarter

on continue leadership for newly in market or remain a instruments We and PhenoCycler. the launched to initiatives paired our First, standalone our spatial of year: the of expand the with balance the following Fusion continued position biology adoption focused

Second, additional drive improvements And chemistry. results. the KOLs discuss clinical will financial new industry and third, over And continue in on turn leading capabilities the panels, biopharma PhenoCycler-Fusion and now our partner launch to to that, with further to universal Joe protein and adoption and translational I research. speed workflow in platform Joe? our call RNA drive of the with to our

Joe Driscoll

everyone. Hello, Brian. Thanks,

instrument growth. $XX.X period, to the million, as total The of first quarter period, and compared XX million, now We in base another was instruments product March prior the as representing $XX in $X.X with year the $X.X for which the strong XX PhenoCyclers $XX.X and in includes were $XX.X includes Within portfolio. XXXX, XX% million, Brian the quarter quarter highlighted, growth. sold, and revenue, representing reagents PhenoImagers. revenue, instruments from installed compared XX%. XX million representing is of Product XX% instruments, PhenoImager software which million first As XXXX, revenue were XXXX was to to growth of XX, PhenoCyclers compared million prior was XXX revenue XXX XXX of total of had which total year of

XX, as XX We of now announce were and been XX system of are a instruments including instrument. March instruments the additional sold PhenoCycler directly total already have five four Fusion installed shipped for as that Fusion combined as a shipped, we from Fusion units. combined either early sold base The upgraded standalone previous a System standalone in or purchases QX have pleased to XXXX, of access

attach tracking Fusion PhenoCycler described. We very to the that efforts are global currently ongoing driven by launch a Brian rate impressive

purchased at to many rate, attachment their microscope our have or XX% prefer microscope have the labs who that existing may factoring PhenoCycler another longer-term needs. However, in remain specific estimates an XX% or already will purchase a based on may

in that XX% period, reagent more and Reagent XXXX. XXXX revenue improvement growth representing Fusion. to XXXX, growth our in versus saw started to a versus standalone QX crucial show customer Reagent significant business million purchasing reagent year $X.X XX% of in quarters the have started we range is increase a we over the of has in tremendous will on Therefore the $X.X combined activity million. part model and in expected QX back XX%. was to strength clarity as patterns corresponding saw to XX% PhenoCycler revenue first is quarter a of of of the pull We we since be COVID compared of to $X.X in Akoya's revenue the subsequent the million Recall units QX quarter. experienced prior for shutdowns growth in that with

Fusion, in early speed instrument two days pull-through utilization. annualized to of combined PhenoImager the three turn PhenoCycler increased pull-through the over $XX,XXX with given the time the but and It that we still for expect times to PhenoCycler both higher annualized the standalone and HT. increase will the compared unit Our exceeds PhenoCycler plex is the per

annual in more volume calls have users users We pull-through volume than disclosed HT than previous pull-through $XXX,XXX more instrument high per annual PhenoImager and instrument. XXX,XXX achieve our of of PhenoCycler per that earnings achieve high

is there pull-through based chemistry. a for reagent So instruments higher the precedent significantly legacy and on

PhenoCycler individual with participating primarily applications. HT to PhenoImager utilization were clinical are CROs The and variety high-volume experience adopters medical labs core multi-omics oncology. Looking high-volume are on or of early consisting power these that varied are development users discovery centers, the in academic a in users a that approach and I/O drug more single cell either biopharma strong of at of translational labs trials, a slide at focus whole of high-volume companies often core seeing the the users, we

solutions representing in the We our throughout period, expect compared million, million and growth rollout universal and pull-through. will drive multi-omic in that year chemistry revenue XXXX growth. XX% plex Services other of totaled higher the and $X.X to prior meaningful XXXX $X.X as

our of a services, operation scaling contribute very has believe significant business, line. solutions, about enthusiastic we to the opportunity are We lab top biopharma services CLIA namely the meaningfully to our this advanced and

in the to orders in for in demand. seeing are November profit CLIA prior quarter, lab have in million to of year profit and increase hired aggressively $XX.X certification resulted in our Following the a we million XXXX, substantial was compared the gross this first margin a service Gross support XX%. period. This $X.X

noncash set the first on pricing million with the a to XXXX. in prior a Operating adoption the million we depreciation, of This offer totaled promotional content launch service the PhenoCycler-Fusion for Throughout early QX to Included from PhenoCycler-Fusion We year company make period. noncash and the the R&D of $XX.X ABS amortization and in expenses is million slight we multi-omic of quarter compared other of in this to ended OpEx the to $XX.X is had investments the quarter made $XX reduction service This of million, did with impact growth. QX capabilities. gross will Margin on speed, $XX expenses to we For the XXXX, future the lab targeted platform. enhance support number cash. near-term as focus $X.X in million investments we impacted margin. in total menu was our somewhat also the and incurred commercial by such continue further items. efforts of orders, a drive as

once year a quarter typically to as that quarter highest annual bonus expenditures happen year other of payments. the of such fiscal first only the and cash The year, each certain is use payments due

the very deliver strong XXXX. ability year, We XXXX which our time, range our longer market. capability to sales in levels of the the the in in provides a options range in see inventory. from global $XX.X across our includes a the biology XX% ample secure our lockdowns outstanding totals portfolio shares initial cash increase in continue shares, invest may record-breaking of as to This quarter addition, the to revenue, we $XX.X the impact Pacific have exceeded QX if million expectations. fully project we tailwinds in another Common higher chain supply will warrants and summarize, distribution in certain consistent million to with $XX $XX.X fiscal are increasing prepayments we We extensive sold product business. impact are runway Asia and any instrument China, of We million of remain diluted million XXXX, instruments they XX of full to are inventory maintaining spatial we suppliers over the of effect which including and barring remain XX In continue as to outstanding March QX cushion this To million. impacts than be revenue challenges. confident that guidance expected. of as Fusion in to business year for and had making to supply end this million $XX our preliminary to $XX growth At

it closing to Now for remarks. over I'll back Brian turn

Brian McKelligon

Joe. you, launch track are announce pleased we very a summary, build our offerings of our menu advantage strong PhenoCycler-Fusion, as exciting and the expand Thank new quarter report In and we the developments on the first-mover in clinic. to

remains questions. ahead from call new spatial Akoya well are of Operator? clinical hard At support the our thankful to our the we opportunities customers growth point, and the as lie open and fellow for for very deliver work dedicated that up this excited markets. as are will Akoyans, about for discovery shareholders. as we the We of well-positioned the the solutions we for

Operator

Instructions] of Piper question Westenberg have [Operator David from you. a Thank Sandler. We

open. Your line is

Dave Westenberg

do that so question, I'm story. ahead. But quarter taking and the I know don't here. for really the launch. Fusion it's I the you I going good and I go to -- Thank the go to on early congrats of commented ahead hope guys. behaviors the don't think And you it's -- Hi, mind. mean you in so the important think you

having guys good. placements my like seasonality going with, about bit. little to that's a just commercial And business? and business like cycles fine us of flush me. really to Starting maybe of QX, NIH are is like the I'm beat I perfectly try you but kind yours of with the budget in typically press say if a remind then, with with with a quarter. nice So course, you the luck of budgets think this Can QX funding in had no, in you

and walk were get that this maybe through able instruments to how us seasonality a you quarter? of you lot can good So

Brian McKelligon

Yeah. Sure.

time. let We David. I'll appreciate question. thanks, So handle Joe that your really

Joe Driscoll

Yes.

past has been few our years. for So consistent business in the the seasonality

So of QX. bit generally little QX Then a QX bit is from a QX of million is generally year. is several QX a little dollars QX. is lowest better. than quarter typically step-up the the better

this So we year. that's expect -- that trajectory

should did somewhat higher kind than QX So from budget we be you million flush the the and QX higher $XX.X expect be you bit of that then than in to QX, QX little as a and QX noted. to

Dave Westenberg

makes Well, it just Okay. mean, I placements pretty the exciting.

you are wanting can but that bump, Fusion, consumables that. that a with least that to immediate about my know and get do -- At about talking and little I you expect early to seeing you press know it I you not in -- you trends, with I talked that you really the again, yet, mentioned an do increase. how you said bit luck mean, want PhenoCycler don't is, the So but have early I

Brian McKelligon

a will it's that. getting sort too happening about I to we're And call it's why in and four from, unit we with increased the of shipments, the think an time installed. up installations be the then the is month just increase. that following saying or XX% throughout a quarter. all reiterate samples talked early with frankly, going closer And would No. David, then of the there's the shipments question. relative what XX%. they're That's most to expectation because happening to per save speed And a generally, just And trainings it, the again, prior on also literally Look, to two plexing the to that fair PhenoCycler, is, the comments average call, median the reality go

to increase have a So time have that's sample And and the alone. talking revenue expected sample three-fold per pull-through you bump. unit we're two you per PhenoCycler bump why in a comments, a over the about

Dave Westenberg

it. Got

you Can about might made get on -- about to better Okay. about but some placement, some that's landscape? or definitely be don't competitive what do think we bit challenges the No, mean, your you macro meeting maybe under competitors -- space. not seem a your the I'm Got in your really bit it. the a them you little relative of throw others to I more the I your talk on customer than bus, asking of definitely to helpful. target having or to want that maybe have. I like not expectations I little -- different had

Brian McKelligon

that talking ones were the And to -- about that type we challenge COVID specifically, challenges, referring the you're are

Dave Westenberg

COVID type of challenges, sales exact kind -- COVID force, them getting labs, out type I the mean thing. a lot into calling of challenges that

Brian McKelligon

at other about we're you for revenue-driven. XX% one COVID So to geographies, example, specific certain way I instrument look think challenges, XX%, the think still China and as

instrument might if But there perhaps so were If geographies, XX% And we we're in consumables, of at were and to that instrumentation why it an different was because impact. those lot -- so instruments get placed less driven story. our one the dominated reason heavily heavily XX%, we a able might is we're side. think be I on those a be of revenue

Dave Westenberg

it. Got

look spatial maybe think helpful. a the your That's there freeze due the thoughts gold, of two-thirds at gold, mean at AGBT? some Any companies. come coming in in the acquiring fact some I at to I stuff the that if then are of the top-tier way out all like the sponsors sponsors the no. lot you out product Any thoughts AGBT might spatial at are there? of line. what And to AGBT. the interesting I biology biology silver, there's down to Okay, attention mean,

Brian McKelligon

take our freezing in don't maybe order. those reverse any so anticipate Well, I purchases. of

they're to And now capabilities freeze. at capabilities the with I main have the energy what think about, I at in to think at But with. is, for breadth as people the it's noted on focused got a largely to part your going today Fusion look we I -- don't and have of and now RNA as of of depth go the don't we team, now point robustness energy the anticipate question, spending we pipeline, your the that's solution talked that I we works and to AGBT, But have first been reason think expect you note, that your eagerness so already and what I we're a we our think is protein. capabilities the why technologies come to the across multi-omic. our expanded AGBT much know

mantra I to you're I again, in have lot requirement. a as standard But going trend still think becoming a where that market to think more area that's the of And we an a start the speed headroom. see is that's is multi-omic.

Dave Westenberg

it. Got

last do here. and last you versus to -- great of Okay. Why one great. do my it's your provider And think it you Because think that what do question. question. my be transcriptomic angle? you next way And after segue this RNA I from sorry, other going the a And adding it's mean that's think going kind you around? the jump actually, is why advantages have or off -- is into I'll that's protein

Brian McKelligon

that. in Thank really when to question image question. I decades is comes we've What and got And mind that ask of David. you like processing. you, image acquisition first that experience

analysis provides a with at to upon. is provides us at. technology, to microscopy I you foundation into do plex, and great the build challenge and ability as protein both the profound area an layer a that's capability a think great that high starting throughput be high multi-omic So to is think And us that I the methodologies technology underlying image that where

Dave Westenberg

very guys. you Okay. much. Perfect. Thank Congrats,

Brian McKelligon

right. David. Thanks, All

Operator

Tejas you. Savant question from Thank Morgan comes next Our Stanley. of Instructions] [Operator

line open. Your is

Edmund Tu

for questions. on Hey, guys. This the Thanks is Tejas. Edmund for taking

Brian McKelligon

Edmund. Hey,

Edmund Tu

wondering, around and different Been this. And between this PhenoCycler I -- year a what PhenoImager a HT? tonight, hopping combined unit how would PhenoCycler-Fusion revenue revenue the a pull-through just missed installation? is expected calls Hey. after But of so the if differ the apologies pull-through after pull-through

Brian McKelligon

Yeah.

with So pull-through. the third-party with about today, average PhenoCycler paired just we're instrument a microscope, doing per of on $XX,XXX

So with Fusion, higher the plexing. paired with to PhenoCycler higher based the the times through two that expect just speed, the we on pull three

So that's really the theory, right now.

And just so in that -- kind we haven't of yet. there's that's on universal going question pull-through, average, going we But with our number are And today, over things really an seen that. These little There's it speak. we of of a in think instruments outlook. as terms installed action getting then so we've a chemistry, grow. mean, that got is lot it. it's I like to things about $XX,XXX, no HT

the we number years. several or to so over want And to XX,XXX XX,XXX up next get that

how of reagent at pull-through. we're kind that's looking So

Edmund Tu

more for based that know your And customer you are that I early the types to any you Thank but specific PhenoCycler-Fusion? gravitating it. be conversations, still Got on days, color. toward it's seem seeing

Brian McKelligon

base the Today customer the similar customer PhenoCycler-Fusion looks base. PhenoCycler to original largely

think to attractive core does it -- have service potential labs is money are that sample making one it is and basis. a on I per more exception labs the

now plexing, and then throughput can per unit higher with you charge time samples more you do higher reasons more per can and obvious sample. For

But what base. the largely base service with with of the the broad strokes in groups. we see to terms PhenoCycler overlapping is is current it standalone more again, directionally, installed So customer attractive

Edmund Tu

do it. early adopters? customer what I being end Got last wondering if that's excitement new launching at about can projects you year? my the question, type of talk was universal around this And the envision guys And chemistry the of you antibody

Brian McKelligon

Yeah. It's good question. a

is So on it's HT the Number leverages groups antibody excitement around the the Opal one, around And that excitement customer using, reasons. to the design it Universal excitement current are the two for panels. the system Universal the example, chemistry, the early technology and base chemistry -- for base it of our currently CODEX. chemistry, does the for underlying really those

workflow have and inventory automation equally important, up the excitement simplification So and having panels an running. that But antibodies the of around tested. is the of get the been to

So are around to And larger the early of running number a to that there is your like panels. large panels. I and studies, excitement be question, are bases, of think panels build the faster PhenoCycler-Fusion large those library panels ability developing have same likely customer I their new think, and customers to

a I it panel it provides. because new of the to benefits think So is lot of around going development be, frankly,

Edmund Tu

Great, thank you.

Operator

Thank you.

of Our next from Canaccord comes Kyle Genuity. question Mikson

Your line open. is

Unidentified Analyst

Thank you.

second So few of and speak Akoya's on a jump and been I've to proprietary prone next advance. that litigation touched be, that I contribute difficulty] you you to not that question differentiation? nature for would other and challenges in is upon the a moreover, to property Kyle [technical you are want differentiated intellectual [indiscernible] not? to apologize just why my can bit, what And apologies. Mikson. company confident But market to the is this is PhenoCycler-Fusion that attributes and confidence already for year IP calls had you the gives given months, if from little what this, so on you've already are it's hearing customers that

Brian McKelligon

that let by reverse selling So in order. market we're me take issued is those on the covered intellectual Everything property.

So we a have strong really portfolio. patent

-- part choppy. question, of a second I bit or The your the little was part first

your hit me So answer. question. Hopefully, let I

other number of market speed on unit samples do proof. time differentiation large to the of comes two to versus speed have the The that continue really down and per ability have future to to a understanding a of the products that PhenoCycler-Fusion got So to workflow. that's build that one we an things. Number platform is the on foundation a

in is whole we ability A huge sciences just high my noted have at markets, standalone unique. it have validate, about do differentiating that ability instruments life -- more the could identify monolithic benefit want earlier very why do for out talking they're thing. the then is as when and about see Fusion system and that discovery. for dual you do rolled single the AGBT. you are forthcoming this to multi-omic plex a that this to thing the in to with classically focused I you And second What slide It comments, The can the workflows, instruments of our two much is multi-omic. that's customers why something it true throughput. as workflow, at higher a RNA sort use is that standalone chemistries the we panels That's that's really we're PhenoCycler-Fusion, that is

protein a run workflow samples doing in So XXX-plex validated the study, swing plex, XXX a XXX you you example, can standalone. manner between Fusion then your can on for and

those things, of slide the So how workflow. whole multi-omic, this cell. think, the speed, are three And dual quickly And really given our the I the pipeline single thirdly, being all the Spatial December for in growing feel confident in announcement to the ability this our since at the expanded expectations XX, meet the has pipeline really we of PhenoCycler-Fusion Day year. of

Unidentified Analyst

you much. Got Thank very it.

Operator

back showing further at I'm any you. turn Brian to no this I'd time. questions remarks. call like over Thank for the to McKelligon closing

Brian McKelligon

rest the we and months. of of everyone, do All the and you, right. weeks Well, soon in forward time. each a Have your appreciate coming to catching great thank it, up you you, and week. look for rest We of and really thank Valerie, day with the

Operator

does conclude today's and Thank this Thank you. call. all conference you participating. gentlemen, Ladies

day. You great may a Have now disconnect.

Akoya Biosciences (AKYA) 8 May 222022 Q1 Earnings call transcript